In support of this hypothesis, we have demonstrated that a proteasome inhibitor (PI), bortezomib, could attenuate podocyte injury and prevent glomerulosclerosis in a mouse model of INF2-R218Q-mediated FSGS, by preventing the UPS-mediated depletion of SD proteins. Here, INF2 is linked to focal segmental glomerulosclerosis.